全文获取类型
收费全文 | 1377篇 |
免费 | 183篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 2篇 |
基础医学 | 136篇 |
临床医学 | 53篇 |
内科学 | 472篇 |
皮肤病学 | 2篇 |
神经病学 | 63篇 |
特种医学 | 2篇 |
外科学 | 5篇 |
综合类 | 3篇 |
预防医学 | 3篇 |
眼科学 | 1篇 |
药学 | 49篇 |
肿瘤学 | 767篇 |
出版年
2023年 | 12篇 |
2022年 | 5篇 |
2021年 | 25篇 |
2020年 | 20篇 |
2019年 | 25篇 |
2018年 | 35篇 |
2017年 | 28篇 |
2016年 | 27篇 |
2015年 | 42篇 |
2014年 | 36篇 |
2013年 | 74篇 |
2012年 | 77篇 |
2011年 | 98篇 |
2010年 | 43篇 |
2009年 | 46篇 |
2008年 | 77篇 |
2007年 | 101篇 |
2006年 | 104篇 |
2005年 | 88篇 |
2004年 | 61篇 |
2003年 | 106篇 |
2002年 | 71篇 |
2001年 | 51篇 |
2000年 | 39篇 |
1999年 | 54篇 |
1998年 | 14篇 |
1997年 | 6篇 |
1996年 | 5篇 |
1995年 | 9篇 |
1994年 | 7篇 |
1993年 | 8篇 |
1992年 | 19篇 |
1991年 | 21篇 |
1990年 | 20篇 |
1989年 | 13篇 |
1988年 | 16篇 |
1987年 | 22篇 |
1986年 | 14篇 |
1985年 | 8篇 |
1984年 | 3篇 |
1983年 | 9篇 |
1982年 | 6篇 |
1977年 | 2篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1967年 | 2篇 |
1965年 | 2篇 |
1964年 | 1篇 |
排序方式: 共有1560条查询结果,搜索用时 40 毫秒
1.
Koji Sasaki Tapan Kadia Kebede Begna Courtney D. DiNardo Gautam Borthakur Nicholas J. Short Nitin Jain Naval Daver Elias Jabbour Guillermo Garcia-Manero Guillermo Montalban Bravo Lucia Masarova Sherry Pierce Marina Konopleva Farhad Ravandi Ayalew Tefferi Hagop Kantarjian 《American journal of hematology》2022,97(1):68-78
The progress with intensive chemotherapy and supportive care measures has improved survival in patients with newly diagnosed acute myeloid leukemia (AML). Given the recent development of effective low intensity therapies, an optimal decision on the therapy intensity may improve survival through the avoidance of early mortality. We reviewed the outcome of 3728 patients with newly diagnosed AML who received intensive chemotherapy between August 1980 and May 2020. Intensive chemotherapy was defined as a cumulative cytarabine dose ≥ 700 mg/m2 during induction therapy. We divided the whole cohort into a training and validation group at a 3:1 ratio. The population was divided into a training (2790 patients) and a validation cohort (938 patients). The median age was 55 years (range, 15-99). Among them, 442 patients (12%) had core-binding factor AML. Binary logistic regression identified older age, worse performance status, hyperbilirubinemia, elevated creatinine, hyperuricemia, cytogenetic abnormalities other than CBF and -Y, and pneumonia as adverse prognostic factors for an early 4-week mortality. This risk classification for early mortality was verified in the validation cohort of patients. In the validation cohort of more recently treated patients from 2000 to 2017, the 4-week mortality rates with intensive chemotherapy were 2%, 14%, and 50% in the low-, high-, and very high-risk group, respectively. The mortality rates with low intensity therapies were 3%, 9%, and 20%, respectively. The risk classification guides treatment intensity by the assessment of age, frailty, organ dysfunction, cytogenetic abnormality, and infection to avoid early mortality. 相似文献
2.
Kiran Naqvi MD Elias Jabbour MD Jeffrey Skinner BS MHA Kristin Anderson BS Sara Dellasala BS Musa Yilmaz MD Alessandra Ferrajoli MD Prithviraj Bose MD Philip Thompson MBBS Yesid Alvarado MD Nitin Jain MBBS Koichi Takahashi MD Jan Burger MD Zeev Estrov MD Gautam Borthakur MBBS Naveen Pemmaraju MD Shilpa Paul Pharm D Jorge Cortes MD Hagop M. Kantarjian MD 《Cancer》2020,126(1):67-75
3.
4.
5.
Hermann Einsele MD Hossein Borghaei DO Robert Z. Orlowski MD Marion Subklewe MD Gail J. Roboz MD Gerhard Zugmaier MD Peter Kufer MD Karim Iskander MD Hagop M. Kantarjian MD 《Cancer》2020,126(14):3192-3201
Immuno-oncology therapies engage the immune system to treat cancer. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation of molecules against tumor-specific antigens, allowing off-the-shelf immuno-oncotherapy. Blinatumomab was the first approved canonical BiTE molecule and targets CD19 surface antigens on B cells, making blinatumomab largely independent of genetic alterations or intracellular escape mechanisms. Additional BiTE molecules in development target other hematologic malignancies (eg, multiple myeloma, acute myeloid leukemia, and B-cell non-Hodgkin lymphoma) and solid tumors (eg, prostate cancer, glioblastoma, gastric cancer, and small-cell lung cancer). BiTE molecules with an extended half-life relative to the canonical BiTE molecules are also being developed. Advances in immuno-oncology made with BiTE technology could substantially improve the treatment of hematologic and solid tumors and offer enhanced activity in combination with other treatments. 相似文献
6.
7.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
8.
Hagop Kantarjian Tapan Kadia Courtney DiNardo Naval Daver Gautam Borthakur Elias Jabbour Guillermo Garcia-Manero Marina Konopleva Farhad Ravandi 《Blood cancer journal》2021,11(2)
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes. The multiple subentities in AML require very different therapies. In this review, we summarize the important pathophysiologies driving AML, review current therapies in standard practice, and address present and future research directions.Subject terms: Prognosis, Health services 相似文献
9.
10.
Rashmi Kanagal-Shamanna MD Guillermo Montalban-Bravo MD Koji Sasaki MD PhD Faezeh Darbaniyan PhD Elias Jabbour MD Carlos Bueso-Ramos MD Yue Wei PhD Kelly Chien MD Tapan Kadia MD Farhad Ravandi MD Gautam Borthakur MD Kelly A. Soltysiak PhD Mark Routbort MD Keyur Patel MD Sherry Pierce RN L. Jeffrey Medeiros MD Hagop M. Kantarjian MD Guillermo Garcia-Manero MD 《Cancer》2021,127(19):3552-3565